Manipulation of cytokines in the management of patients with inflammatory bowel disease

References

• Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182–205
   PubMed Web of Science ®Google Scholar
• Janeway CA, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994; 76: 275–85
   PubMed Web of Science ®Google Scholar
• Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998; 280: 243–8
   PubMed Web of Science ®Google Scholar
• Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 227–57
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138–46
   PubMedGoogle Scholar
• Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787–93
   PubMed Web of Science ®Google Scholar
• Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Ann Rev Immunol 1998; 16: 137–61
   PubMed Web of Science ®Google Scholar
• Strober W, Ludviksson BR, Fuss IJ. The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn's disease. Ann Intern Med 1998; 128: 848–56
   PubMed Web of Science ®Google Scholar
• Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT. Interleukin-2-and interferon-gamma secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993; 78: 127–31
   PubMed Web of Science ®Google Scholar
• Fais S, Capobianchi MR, Pallone F, Di Marco P, Boirivant M, Dianzani F. Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers. Gut 1991; 32: 403–7
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Neurath M, Boirivant M, Klein JS, De la Motte C, Strong SA. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas Ulcerative Colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261–70
   PubMed Web of Science ®Google Scholar
• Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997; 112: 1169–78
   PubMed Web of Science ®Google Scholar
• Monteleone G, Trapasso F, Parrello T, Biancone L, Stella A, Luliano R. Bioactive interleukin-18 expression is up-regulated in Crohn's disease. J Immunol 1999; 163: 143–7
   PubMed Web of Science ®Google Scholar
• Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Erhardt R. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today 1997; 18: 61–4
   PubMedGoogle Scholar
• Boirivant M, Marini M, Di Felice G, Pronio AM, Montesani C, Terisigni R. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999; 116: 557–65
   PubMed Web of Science ®Google Scholar
• Ina K, Itoh J, Fukushima K, Kusugami K, Yamaguchi T, Kyokane K. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999; 163: 1081–90
   PubMed Web of Science ®Google Scholar
• Kelt K, Rognum TO, Brandtzaeg P. Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon. Gastroenterology 1987; 93: 919–24
   PubMed Web of Science ®Google Scholar
• Das KM, Dasguptaandal A, Geng X. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism for ulcerative colitis. J Immunol 1993; 150: 2487–93
   PubMed Web of Science ®Google Scholar
• Duerr RH, Targan SR, Landers CJ, La Russo NF, Lindslay KL, Wiesner RH. Neutrophil cytoplasmic antibodies: a link between sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100: 1385–91
   PubMed Web of Science ®Google Scholar
• Biancone L, Mandal A, Yang H, Dasgupta T, Paoluzi AO, Marcheggiano A. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology 1995; 109: 3–12
   PubMed Web of Science ®Google Scholar
• Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin Gl and activated complement colocalise with the M(r) 40 KD putative autoantigen in ulcerative colitis. Gut 1993; 34: 650–7
   PubMed Web of Science ®Google Scholar
• Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990; 98: 464–8
   PubMed Web of Science ®Google Scholar
• Sartor RB. Pathogenetic and clinical relevance of cytokines in inflammatory bowel disease. Immunol Res 1991; 10: 465–71
   PubMed Web of Science ®Google Scholar
• Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455–66
   PubMed Web of Science ®Google Scholar
• Van Deventer SJH. Tumour necrosis factor and Crohn's disease. Gut 1997; 40: 443–8
   PubMed Web of Science ®Google Scholar
• Van Dullemen H, Meenan J, Stronkhorst A, Tytgat GNJ, Van Deventer SJH. Mediators of mucosal inflammation: implications for therapy. Scand J Gastroenterol 1997; 32: 92–8, Suppl 223
   Web of Science ®Google Scholar
• MacDonald TT, Bajaj-Elliott M, Pender SLF. T cells orchestrate intestinal mucosai shape and integrity. Immunol Today 1999; 20: 505–10
   PubMedGoogle Scholar
• MacDonald TT, Monteleone G, Pender SLF. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 2000; 51: 2–9
   PubMed Web of Science ®Google Scholar
• Pender SLF, Fell JME, Chamow SM, Ashkenazi A, MacDonald TT. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998; 160: 4098–103
   PubMed Web of Science ®Google Scholar
• Pender SLF, Tickle SP, Docherty AJP, Howie D, Wathen NC, MacDonald TT. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997; 158: 1582–90
   PubMed Web of Science ®Google Scholar
• Monteleone G, MacDonald TT, Wathen NC, Pallone F, Pender SLF. Enhancing lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gaslroenterology 1999; 117: 1069–77
   PubMed Web of Science ®Google Scholar
• Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, Kere J, Saarialho-Kere U. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP13), macrophage metalloelastase (MMP12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 1998; 152: 1005–14
   PubMed Web of Science ®Google Scholar
• Saarialho-Kere U, Vaalamo M, Puolakkainen P, Airola K, Parks WC, Karjalainen-Lindsberg ML. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 1996; 148: 519–26
   PubMed Web of Science ®Google Scholar
• Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat G. Tumor necrosis factor antibody treatment in Crohn's disease. Lancet 1993; 342: 173–4
   PubMed Web of Science ®Google Scholar
• Van Dullemen HM, Van Deventer SJH, Hommes DW, Bjil HA, Jansen J, Tytgat GNJ. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129–35
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, Van Deventer SJH, Mayer L, Present DH, Braakman T. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997; 337: 1029–35
   PubMed Web of Science ®Google Scholar
• Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D. A role for TNF-alpha and mucosai T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159: 6276–82
   PubMed Web of Science ®Google Scholar
• D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: an European multicenter trial. Gastroenterology 1999; 116: 1029–34
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Haens G D., Targan S, Vasiliauskas E, Hanuer S B, Present DH. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761–9
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398–405
   PubMed Web of Science ®Google Scholar
• Ricart E, Panaccione R, Loftus EV, Tramine WJ, Sandborn WJ. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology 1999; 117: 429–32
   PubMed Web of Science ®Google Scholar
• Sands BE, Podolsky DK, Tremaine WJ. Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis (UC). Gastroenterology 1996; 110: A1008
   PubMed Web of Science ®Google Scholar
• Van Hogezand RA, Verspaget HW. New therapies for inflammatory bowel disease: an update on chimeric anti-TNF-alpha antibodies and IL-10 therapy. Scand J Gastroenterol Suppl 1997; 223: 105–7
   PubMedGoogle Scholar
• Baert FJ, D'haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D. Tumor necrosis factor-alpha antibody (Infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22–8
   PubMed Web of Science ®Google Scholar
• Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997; 349: 521–4
   PubMed Web of Science ®Google Scholar
• Evans RC, Clark L, Heath P, Rhodes JM. Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571. Gastroenterology 1996; 110: A905
   Web of Science ®Google Scholar
• Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997; 40: 470–4
   PubMed Web of Science ®Google Scholar
• Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 1224–34
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Ziotnik A, Vieira P, Mosmann TR, Howard M, Moore KW. IL-10 acts on the antigen-presenting cells to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444–51
   PubMed Web of Science ®Google Scholar
• Kuhn R, Lohier J, Rennick D. Interleukin-10 deficient mice develop chronic enterocolitis. Cell 1993; 75: 263–74
   PubMed Web of Science ®Google Scholar
• Sellon RK, Tonkonology S, Schultz M, Dieleman LA, Grenther W, Balish E. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66: 5224–31
   PubMed Web of Science ®Google Scholar
• Schreiber S, Heinig T, Thiele HG, Raedler A. Immuno-regulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 1434–44
   PubMed Web of Science ®Google Scholar
• Van Deventer SJH, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997; 113: 383–9
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G. Safety, tolerance and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn's disease (STEMM-CD). Gastroenterology 1998; 114: A974
   Web of Science ®Google Scholar
• Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams NC, Jacyna M. A safety and efficacy study of recombinant human interluekin-10 (rHuIL-10) treatment in 329 patients with chronic active Crohn's disease (CACD). Gastroenterology 1998; 114: A1080
   Web of Science ®Google Scholar
• Schreiber S, Fedorak RN, Wild G, Gangl A, Targan S, Jacyna M. Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis. Gastroenterology 1998; 114: A1080
   Web of Science ®Google Scholar
• Grosfeld JL, Du X, Williams DA. Interleukin-11: its biology and prospects for clinical use. J Parenter Enteral Nutr 1999; 23: S67–9, (5 Suppl)
   PubMed Web of Science ®Google Scholar
• Trepicchio WL, Wang L, Bozza M, Dorner AJ. IL. regulates macrophage effector function through the inhibition of nuclear factor-Kappa B. J Immunol 1997; 159: 5661–70
   PubMed Web of Science ®Google Scholar
• Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117: 58–64
   PubMed Web of Science ®Google Scholar
• Sands BE, Podolsky DK. New life in a sleeper: thalidomide and Crohn's disease. Gastroenterology 1999; 117: 1485–8
   PubMed Web of Science ®Google Scholar
• Erhenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117: 1271–7
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117: 1278–87
   PubMed Web of Science ®Google Scholar
• Yanamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000; 164: 4878–82
   PubMed Web of Science ®Google Scholar
• Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S. Blockade of interleukin 6 transsignaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat Med 2000; 6: 583–8
   PubMed Web of Science ®Google Scholar
• Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to IL-12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281–90
   PubMed Web of Science ®Google Scholar
• Fuss I J, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999; 117: 1078–88
   PubMed Web of Science ®Google Scholar
• Neurath MF, Becker C, Barbulescu K. Role of NF-kappaB in immune and inflammatory responses in the gut. Gut 1998; 43: 856–60
   PubMed Web of Science ®Google Scholar
• Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappaB in inflammatory bowel disease. Gut 1998; 42: 477–84
   PubMed Web of Science ®Google Scholar
• Neurath MF, Petterson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappaB abrogates established experimental colitis in mice. Nat Med 1996; 2: 998–1004
   PubMed Web of Science ®Google Scholar